• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20046 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the use of the new tools 2.0 and the social web in the diffusion and dissemination of the products of the agencies and units of Health Technology Assessment]
1998     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of the use of antidigoxin antibodies in the treatment of digitalis intoxication]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the scientific evidence on nipple-areola complex micropigmentation, requirements for its proper implementation and costs]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of the potential of real-time 3-dimensional echocardiography in the assessment of right ventricular function in adult congenital heart disease: comparison of RT-3D echo with MRI]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the implementation of clinical guidelines in the Basque Country. Cluster randomized trial]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Evaluation of the impact in inequality before and after the enhancement of health insurance coverage of cancer]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of the evidence on the HeartMate II and HeartWare ventricular assist devices for the treatment of chronic end-stage heart failure]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the efficacy and safety of negative pressure in the treatment of chronic wounds]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the effectiveness of psychological intervention in the first psychotic episode by multidisciplinary treatment]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Evaluation of the Danish National Cancer Action Plan - status and future monitoring - summary and proposals for focus areas]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Evaluation of the change in medical services before and after the enhancement of health insurance coverage of cancer]
2003     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of techniques for detecting breast implant rupture]
2011     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of surrogate variables in oncology. Advanced and metastatic breast cancer]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of subcutaneous-lead implantable cardioverter-defibrillators]
2021     Norwegian Institute of Public Health (NIPH) [Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of optical coherence tomography in the diagnosis of age related macular degeneration compared with fluorescence angiography]
2010     Haute Autorite de sante (HAS) [Evaluation of negative-pressure wound therapy]
2011     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Evaluation of multiple technologies for chronic wounds and burns]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of bariatric surgery (obesity surgery) versus conservative strategies in adult patients with morbid obesity]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of l-caldesmon as biomarker for brain tumor monitoring]
2009     Finnish Office for Health Care Technology Assessment (Finohta) [Evaluation of implementation of foetal screening]
2016     Haute Autorite de sante (HAS) [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of ethylene oxide sterilant alternatives: plasma and ozone]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficiency of organizational models for stroke management (stroke units)]
2013     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficacy and safety of PET-CT (update)]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Evaluation of diagnostic technologies - background, challenges, methods]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of care times for the main cancer sites: colon/rectum, lung, breast and prostate]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of care quality in the national health service towards severe childhood mental disorders. A study in infant/juvenile mental health services]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of bubble humidification systems in low-flow oxygen therapy. Systematic review and cost analysis]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation and impact of a primary care-based telemonitoring intervention in home care patients with heart failure or chronic lung disease. Randomised controlled trial. The TELBIL study]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluating the implementation of diagnostic telemedicine in the field of dermatology]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [ETIAMEST I & II: Highlights]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Addendum]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Etanercept in patients with juvenile idiopathic arthritis: systematic review and economic evaluation]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Estimation of incidence of urinary incontinence associated with pregnancy and childbirth]
2003     Center for Medical Technology Assessment (CMT) [Estimating health care need]
2013     Andalusian Health Technology Assessment Area (AETSA) [Esteem® totally implantable hearing device for treatment of sensorineural hearing loss. Systematic review]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Establishing standards, records and analytical procedures for the treatment of ulcerative colitis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Addendum to Commission A21-25]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin/sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Addendum to Commission A21-158]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (liposarcoma) - Addendum A16-31
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (Addendum to Commission A14-25)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Erenumab in migraine prevention]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2009     Committee for New Health Technology Assessment (CNHTA) [ERCC1 RNA RT-PCR quantification]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) for COVID-19]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus VCA IgA]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus EA IgA]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Epoetin (EPO) for anaemic cancer patients]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Epileptic source localization with EEG-correlated functional MRI]
2018     Andalusian Health Technology Assessment Area (AETSA) [Epigenetic profile for the identification of primary cancer of unknown origin]
2018     Canary Health Service [Epidermal growth factor for the treatment of diabetic foot ulcers]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Epidermal growth factor (Heberprot-P®) in chronic ulcers]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Epidemiology of long COVID: a preliminary report. German short version of the original KCE report]
2003     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Epidemiology and costs of osteoarthritis and rheumatoid arthritis in Hungary]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Epidemiological analysis of information collected by hospital cancer registries in the Basque Autonomous Community. Identification of possible improvements with regard to the feedback and dissemination of results]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzyme replacement therapy in mucopolysaccharidoses I, II and VI; 2011]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzymatic replacement treatment for type I gaucher's disease patients]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A21-77]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A18-80]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Addendum to Commission A20-74]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Addendum to Commission A20-75]
2011     Committee for New Health Technology Assessment (CNHTA) [Enterovirus real-time rt-pcr]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Enhancing the quality of information on colorectal and prostate cancer in the population cancer register of the Basque Country (RCE) and bibliographical review]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endovascular treatment of varicose veins by radiofrequency ablation or cyanoacrylate closure]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment for thoracic aorta lesions]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment for thoracic aorta lesions]
2016     Haute Autorite de sante (HAS) [Endovascular thrombectomy of intracranial arteries]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke. National Report: German Summary of the correspondent EUnetHTA Report]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular repair of thoracic and thoraco-abdominal aortic aneurysm]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular repair of aortic aneurysms]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular repair in abdominal aortic aneurysm]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment versus saphenectomy for the management of varicose veins in lower limbs]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment of varicose veins of the lower limbs]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Assessment according to §137h Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Addendum to commission H20-08]